Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...

Indications include newly diagnosed chronic-phase Ph+ CML and chronic/accelerated-phase disease after resistance or intolerance to prior therapy, including imatinib. Concomitant use with PPIs and ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

The ODT formulation utilizes proprietary technology to improve solubility and dissolution rates, maintaining bioavailability even when taken concomitantly with acid-reducing therapies. The Food and ...